4.7 Article

Recommendations for the Use of Prolonged-Release Fampridine in Patients with Multiple Sclerosis (MS)

Journal

CNS NEUROSCIENCE & THERAPEUTICS
Volume 19, Issue 5, Pages 302-306

Publisher

WILEY-BLACKWELL
DOI: 10.1111/cns.12101

Keywords

Aminopyridines; Fampridine; Multiple sclerosis; Walking

Funding

  1. MSM [0021620849]
  2. Biogen Idec
  3. Novartis
  4. Ministry of Health for MS research
  5. [PRVOUK-P26/LF1/4]

Ask authors/readers for more resources

Prolonged-release fampridine (fampridine PR) is a potassium channel blocker that improves conductivity of signal on demyelinated axons in central nervous system. Fampridine PR has been approved to improve speed of walking in patients with multiple sclerosis. This statement provides a brief summary of data on fampridine PR and recommendations on practical use of the medication in clinical practice, prediction, and evaluation of response to treatment and patient management.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available